Pharmafile Logo
Pharmafocus logo
Advanced Search

Actos

Showing 12 posts of 12 posts found.

Actos image

Takeda pays $2.7 billion to settle Actos lawsuits

May 1, 2015
Sales and Marketing Actos, FDA, Takeda, bladder, lilly, pioglitazone, type 2

Takeda has agreed to pay $2.7 billion to finally settle thousands of US lawsuits claiming its diabetes drug Actos can …

News
Actos image

Takeda offers $2.2 billion to resolve Actos damages claims

April 1, 2015
Sales and Marketing Actos, Cancer, Takeda, bladder, diabetes, heart, pioglitazone

Takeda has attempted to settle its hefty damages bill over claims it was hiding cancer risks in its diabetes drug …

News
Christophe Weber image

New chief executive for Takeda

March 4, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actos, Millennium, Nycomed, Takeda, Yasuchika Hasegawa, christophe weber

Japanese pharma giant Takeda has added the title of chief executive to its representative director, president and chief operating officer …

News
Actos image

Analysis finds no Actos bladder cancer link

December 8, 2014
Sales and Marketing Actos, Cancer, Takeda, bladder, lilly, pioglitazone, type 2

A large-scale analysis of patient data has found that pioglitazone, the diabetes drug that is the subject of ongoing safety …

News
Actos image

Takeda and Lilly get Actos trial reprieve

October 29, 2014
Sales and Marketing Actos, Takeda, bladder cancer, diabetes, lilly

A judge has dramatically reduced the $9 billion damages bill Takeda and Lilly were set to pay over safety allegations …

News
takeda__actos__pioglitazone

Takeda and Lilly hit with $9 billion Actos damages bill

April 8, 2014
Medical Communications, Sales and Marketing Actos, Takeda, law case, lilly

A US jury has ordered Japanese firm Takeda Pharmaceutical to pay $6 billion (£3.6 billion) in punitive damages, over claims …

News
Takeda's Actos

Generic Actos gains FDA approval

August 20, 2012
Sales and Marketing Actos, Mylan, Ranbaxy, Takeda, diabetes, generic

Takeda’s big-selling diabetes pill Actos will have its US sales decimated after the FDA approves three copycat versions of the …

News
Gilenya picture

Key product launches of 2011

December 19, 2011
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products

 Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …

Feature

European reprieve for Takeda’s Actos

July 22, 2011
Sales and Marketing Actos, diabetes

Takeda’s Actos is likely to remain on the market in Europe but regulators want the diabetes drug to carry stronger …

News

Takeda forced to withdraw Actos in France

July 11, 2011
Sales and Marketing Actos, Competact, Takeda, diabetes

Takeda has officially taken its diabetes drug Actos off the market in France at the request of the country’s medicines …

News
Takeda Actos (pioglitazone)

France pulls Takeda diabetes drugs after cancer fears

June 13, 2011
Sales and Marketing Actos, Competact, EMA, Takeda

The French medicines agency has moved to prevent two Takeda diabetes drugs from being prescribed after fears they could increase …

News

FDA launches safety review of Actos

September 20, 2010
Sales and Marketing Actos, Takeda, diabetes

A new safety review of Takeda’s diabetes drug Actos has been launched by the FDA after a long-term study suggested …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026